Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma
Am Health Drug Benefits
.
2015 Mar;8(Spec Feature):135-40.
Author
Lisa Raedler
PMID:
26629279
PMCID:
PMC4665054
No abstract available